ChemoCentryx repays, terminates loan early with Hercules Capital

By Mary-Katherine Stinson

Lexington, Ky., Oct. 20 – ChemoCentryx, Inc. repaid in full and terminated its credit facility early with Hercules Capital, Inc. on Oct. 20, according to an 8-K filing with the Securities and Exchange Commission.

The end-of-term and prepayment charges for the amended and restated loan and security agreement totaled $1,734,129.14.

The $100 million four-year credit facility was dated Jan. 8, 2020.

The early repayment was in connection with ChemoCentryx’s completed merger with and acquisition by Amgen Inc. which also closed Oct. 20 for a total consideration of approximately $3.7 billion.

The clinical-stage biopharmaceutical company is based in San Carlos, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.